Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab

Ocular Immunology and Inflammation

Volumn 21, Issue 6, 2013, Pages 468-474

  Al Rashidi, Sultan ^a   Al Fawaz, Abdullah ^a   Kangave, Dustan ^a   Abu El Asrar, Ahmed M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Anti tumor necrosis factor antibody; Beh et disease; Biologics; Infliximab; Uveitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ARTICLE; BEHCET DISEASE; CATARACT EXTRACTION; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE SURGERY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; MALE; OUTCOME ASSESSMENT; REFRACTORY UVEITIS; RELAPSE; REMISSION; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; SCLERECTOMY; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CHILD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INFUSIONS, INTRAVENOUS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, POSTERIOR; VISUAL ACUITY; YOUNG ADULT;

EID: 84884926371     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2013.779727     Document Type: Article

References (46)

1. International Study Group for behçet' s Disease. Criteria for diagnosis of behçet' s disease. Lancet. 1990; 335: 1078-1080
2. Sakane T, Takeno M. New approaches to Behçet' s disease. Exp Opin Invest Drugs. 2000; 9: 1993-2005
3. Tugal-Tukun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in behçet' s disease: An analysis of 880 patients. Am J Ophthalmol. 2004; 138: 373-380
4. El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011; 139: 177-184
5. El-Asrar AM, Al-Obeidan SS, Kangave D, et al. CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology. 2011; 216: 1004-1009
6. Mage JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in behçet' s disease: A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993; 20: 1544-1549
7. Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with behçet' s disease treated with infliximab. Cytokine. 2003; 24: 210-218
8. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in behçet' s disease: Soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997; 24: 128-132
9. Evereklioglu C, Er H, Turkoz Y, et al. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with behçet' s disease. Mediators Inflamm. 2002; 11: 87-93
10. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in behçet' s disease with ocular involvement. Ocul Immunol Inflamm. 2004; 12: 53-58
11. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factoralpha in clinical uveitis. Ophthalmic Res. 2001; 33: 251-255
12. Greiner K, Murphy CC, Willermain F, et al. Anti-TNF a therapy modulates the phenotype of peripheral blood CD4þ Tcells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004; 45: 170-176
13. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades-Behçet' s disease. Ann Intern Med. 2004; 140: 404-406
14. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet' s disease. Arthritis Rheum. 2005; 52: 2478-2484
15. Ohno S, Makamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in behçet' s disease with refractory uveoretinitis. J Rheumatol. 2004; 31: 1362-1368
16. Lantbier N, Parc C, Scavennec R, et al. Infliximab in the treatment of posterior uveitis in behçet' s disease: Long term follow-up in four patients. Press Med. 2005; 34: 916-918
17. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet' s disease. Clin Exp Rheumatol. 2004; 22: S14-S16
18. Abu El-Asrar AM, Abboud EB, Aldibhi H, et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet' s disease. Int Ophthalmol. 2005; 26: 83-92
19. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of behçet' s disease: A 24-month follow-up study. Rheumatology (Oxford). 2007; 46: 1161-1164
20. Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active Behçet' s uveitis: An open-label trial. Rheumatol Int. 2008; 29: 53-57
21. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of behçet' s disease. Jpn J Ophthalmol. 2007; 51: 191-196
22. Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with behçet' s disease on infliximab therapy. Br J Ophthalmol. 2011; 95: 1245-1250
23. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in behçet' s disease. Am J Ophthalmol. 2008; 146: 845-850
24. Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with behçet' s disease: Advantages and controversial aspects. Ann N Y Acad Sci. 2007; 1110: 474-484
25. Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with behçet' s disease. Ocul Immunol Inflamm 2012; 20: 193-197
26. Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of behçet' s disease. Ocul Immunol Inflamm. 2012; 20: 198-202
27. Okada AA, Goto H, Ohno S, Mochizuki M. Ocular behçet' s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in behçet' s disease. Arch Ophthalmol. 2012; 130: 592-598
28. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet' s disease receiving infliximab treatment. Br J Ophthalmol. 2011; 95: 205-208
29. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol. 2011; 95: 549-552
30. Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in behcet' s disease. Invest Ophthalmol Vis Sci. 2011; 52: 476-484
31. Ozdal PC, Ortaç S, Taşkintuna I, Firat E. Posterior segment involvement in ocular behçet' s disease. Eur J Ophthalmol. 2002; 12: 424-431
32. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cycstoid macular edema associated with uveitis. Am J Ophthalmol. 2004; 138: 648-650
33. Noda E, Yamanishi S, Shiraishi A, Ohashi Y. Cataract surgery under infliximab therapy in a patient with behçet' s disease. J Ocul Pharmacol Ther. 2009; 25: 467-470
34. Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for behçet disease. Jpn J Ophthalmol. 2010; 54: 360-361
35. Nishida T, Shibuya E, Asukata Y, et al. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with behçet' s disease. Case Rep Ophthalmol. 2011; 2: 189-192
36. Elezoglou A, Kafasi N, Kaklamanis PH, et al. Infliximab treatment-induced formation of autoantibodies is common in behçet' s disease. Clin Exp Rheumatol. 2007; 25: S65-S69
37. Iwata D, Namba K, Mizuuchi K, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of behçet' s disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012; 250: 1081-1087
38. Adá n A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of behçet' s disease after withdrawal of infusions. Int Ophthalmol. 2010; 30: 577-581
39. Quinn MA, Conaghan PG, O' Connor PJ, et al. Very early treatment with infliximab in addition to metrotrexate in early, poor- rognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, pacebo-controlled trial. Arthritis Rheum. 2005; 51: 27-35
40. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007; 56: 2129-2134
41. Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol. 2007; 13: 5238-5244
42. Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of behçet' s disease: Experience in 19 patients. Rheumatology (Oxford). 2012; 51: 1825-1831
43. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular behçet' s disease. Ocul Immunol Inflamm. 2010; 18: 226-232
44. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in behçet' s disease. Eye (Lond). 2007; 21: 824-825
45. Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet' s disease-related uveitis. Rheumatol Int. 2011; 31: 243-245
46. Olivieri I, Leccese P, D' Angelo S, et al. Efficacy of adalimumab in patients with behçet' s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011; 29: S54-S57